On the Horizon

4199

Exenatide (synthetic exendin-4) significantly reduced A1C in patients with type 2 diabetes who were failing maximum doses of a sulfonylurea, according to researchers at the University of North Carolina School of Medicine in Chapel Hill, North Carolina, and the Veterans Medical Center at the University of California San Diego. Exenatide was well tolerated and associated with weight loss.

In a 30-week study conducted at 101 sites in the United States, 377 subjects were randomized to receive exenatide injected subcutaneously twice daily (before breakfast and dinner) or placebo.

The most common adverse events were generally mild or moderate and gastrointestinal in nature. No severe hypoglycemia was observed.

Click here to view/write comments
Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.